Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis

BACKGROUND: Nonetheless biologic modifier therapies are available treatment strategies for sight-threatening uveitis in children, the lack of evidence from head-to-head randomized controlled studies limits our understanding of timing of therapy when to commence therapy, which agent to choose and how...

Descripción completa

Detalles Bibliográficos
Autores principales: Simonini, Gabriele, Taddio, Andrea, Cattalini, Marco, Caputo, Roberto, de Libero, Cinzia, Parentin, Fulvio, Pagnini, Ilaria, Lepore, Loredana, Cimaz, Rolando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637103/
https://www.ncbi.nlm.nih.gov/pubmed/23587261
http://dx.doi.org/10.1186/1546-0096-11-16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637103/
https://www.ncbi.nlm.nih.gov/pubmed/23587261
http://dx.doi.org/10.1186/1546-0096-11-16

Ejemplares similares